Update on regulatory review of aducanumab ,a proposed treatment for Alzheimer's disease, in the European Union.
Following an oral explanation held at the November meeting of the CHMP, Biogen received a negative trend vote on the aducanumab Marketing Authorization Application. The CHMP is expected to adopt a formal opinion on the Marketing Authorization Application at its December meeting (December 13-16, 2021). Biogen will continue to engage with the EMA and CHMP as it considers next steps towards the goal of providing access to aducanumab to patients in Europe.
At the recent Clinical Trials on Alzheimer’s Disease conference (CTAD), Biogen announced new Phase III findings that provide further evidence of aducanumab’s effect on lowering amyloid beta plaque and downstream tau pathology, the two defining pathologies of Alzheimer’s disease..
Related news and insights
Clover Biopharmaceuticals, Ltd. announced positive data from its ongoing Phase III study evaluating Clover’s SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine candidate
NICE recommendation for upadacitinib as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if: i. tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and iithe company provides upadacitinib according to the commercial arrangement
Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: i. tumours have the programmed cell death ligand 1 (PD L1) biomarker expression on 50% or more of their tumour cells and ii. whose disease has not progressed after platinum-based adjuvant chemotherapy